S&P 500   3,909.32 (+2.58%)
DOW   31,602.82 (+2.17%)
QQQ   323.61 (+3.01%)
AAPL   127.50 (+5.15%)
MSFT   236.98 (+1.98%)
FB   266.15 (+3.31%)
GOOGL   2,069.97 (+2.38%)
TSLA   713.92 (+5.69%)
AMZN   3,141.47 (+1.57%)
NVDA   550.13 (+0.28%)
BABA   241.58 (+1.61%)
CGC   34.72 (+6.02%)
GE   13.21 (+5.34%)
MU   94.68 (+3.44%)
NIO   49.72 (+8.61%)
AMD   86.36 (+2.19%)
T   28.17 (+1.00%)
F   12.04 (+2.91%)
ACB   11.12 (+5.70%)
DIS   195.23 (+3.27%)
BA   224.78 (+6.02%)
NFLX   549.87 (+2.05%)
BAC   36.00 (+3.72%)
S&P 500   3,909.32 (+2.58%)
DOW   31,602.82 (+2.17%)
QQQ   323.61 (+3.01%)
AAPL   127.50 (+5.15%)
MSFT   236.98 (+1.98%)
FB   266.15 (+3.31%)
GOOGL   2,069.97 (+2.38%)
TSLA   713.92 (+5.69%)
AMZN   3,141.47 (+1.57%)
NVDA   550.13 (+0.28%)
BABA   241.58 (+1.61%)
CGC   34.72 (+6.02%)
GE   13.21 (+5.34%)
MU   94.68 (+3.44%)
NIO   49.72 (+8.61%)
AMD   86.36 (+2.19%)
T   28.17 (+1.00%)
F   12.04 (+2.91%)
ACB   11.12 (+5.70%)
DIS   195.23 (+3.27%)
BA   224.78 (+6.02%)
NFLX   549.87 (+2.05%)
BAC   36.00 (+3.72%)
S&P 500   3,909.32 (+2.58%)
DOW   31,602.82 (+2.17%)
QQQ   323.61 (+3.01%)
AAPL   127.50 (+5.15%)
MSFT   236.98 (+1.98%)
FB   266.15 (+3.31%)
GOOGL   2,069.97 (+2.38%)
TSLA   713.92 (+5.69%)
AMZN   3,141.47 (+1.57%)
NVDA   550.13 (+0.28%)
BABA   241.58 (+1.61%)
CGC   34.72 (+6.02%)
GE   13.21 (+5.34%)
MU   94.68 (+3.44%)
NIO   49.72 (+8.61%)
AMD   86.36 (+2.19%)
T   28.17 (+1.00%)
F   12.04 (+2.91%)
ACB   11.12 (+5.70%)
DIS   195.23 (+3.27%)
BA   224.78 (+6.02%)
NFLX   549.87 (+2.05%)
BAC   36.00 (+3.72%)
S&P 500   3,909.32 (+2.58%)
DOW   31,602.82 (+2.17%)
QQQ   323.61 (+3.01%)
AAPL   127.50 (+5.15%)
MSFT   236.98 (+1.98%)
FB   266.15 (+3.31%)
GOOGL   2,069.97 (+2.38%)
TSLA   713.92 (+5.69%)
AMZN   3,141.47 (+1.57%)
NVDA   550.13 (+0.28%)
BABA   241.58 (+1.61%)
CGC   34.72 (+6.02%)
GE   13.21 (+5.34%)
MU   94.68 (+3.44%)
NIO   49.72 (+8.61%)
AMD   86.36 (+2.19%)
T   28.17 (+1.00%)
F   12.04 (+2.91%)
ACB   11.12 (+5.70%)
DIS   195.23 (+3.27%)
BA   224.78 (+6.02%)
NFLX   549.87 (+2.05%)
BAC   36.00 (+3.72%)
Log in
OTCMKTS:OPHLY

Ono Pharmaceutical Stock Forecast, Price & News

$8.94
-0.24 (-2.61 %)
(As of 02/26/2021 10:07 PM ET)
Add
Compare
Today's Range
$8.92
Now: $8.94
$9.24
50-Day Range
$9.18
MA: $9.79
$10.28
52-Week Range
$5.25
Now: $8.94
$10.93
Volume3,800 shs
Average Volume30,950 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors. It also provides GLACTIV and FORXIGA tablets for type 2 diabetes; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; PARSABIV, an intravenous injection for dialysis patients; ONOACT injections for tachyarrhythmia; STAYBLA tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; CORALAN for treatment of chronic heart failure; and RECALBON tablets for osteoporosis. In addition, the company is developing products for colorectal, esophageal, gastric or esophago-gastric junction, small and non-small cell lung, ovarian, pancreatic, prostate, biliary tract, hematologic, and head and neck cancers; hepatocellular, urothelial, and virus positive/negative solid carcinoma; glioblastoma; multiple myeloma; malignant pleural mesothelioma; solid tumors; central nervous system, primary testicular, and lymphoplasmacytic; acute myeloid leukemia; melanoma; primary macroglobulinemia; chronic heart failure; Parkinson's disease; structural damage of the joints in rheumatoid arthritis; polymyositis/dermatomyositis; osteoarthritis; enthesopathy; pemphigus; celebral infarction; acromegaly; thrombosis; and autoimmune disease. The company has research and option agreement with Numab Therapeutics AG. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.

Industry, Sector and Symbol

Industry Pharmaceuticals: Other
Sub-IndustryN/A
Current SymbolOTCMKTS:OPHLY
CUSIPN/A
CIKN/A
Phone(166) 263-5670
Employees3,560
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.48 out of 5 stars

Health Technology Sector

16th out of 19 stocks

Pharmaceuticals: Other Industry

4th out of 6 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$8.94
-0.24 (-2.61 %)
(As of 02/26/2021 10:07 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OPHLY News and Ratings via Email

Sign-up to receive the latest news and ratings for OPHLY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ono Pharmaceutical (OTCMKTS:OPHLY) Frequently Asked Questions

Is Ono Pharmaceutical a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ono Pharmaceutical in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ono Pharmaceutical stock.
View analyst ratings for Ono Pharmaceutical
or view top-rated stocks.

What stocks does MarketBeat like better than Ono Pharmaceutical?

Wall Street analysts have given Ono Pharmaceutical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ono Pharmaceutical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Ono Pharmaceutical?

Ono Pharmaceutical saw a drop in short interest during the month of February. As of February 12th, there was short interest totaling 100 shares, a drop of 95.7% from the January 28th total of 2,300 shares. Based on an average trading volume of 205,700 shares, the days-to-cover ratio is presently 0.0 days.
View Ono Pharmaceutical's Short Interest
.

How has Ono Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

Ono Pharmaceutical's stock was trading at $6.45 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OPHLY stock has increased by 38.6% and is now trading at $8.94.
View which stocks have been most impacted by COVID-19
.

Who are Ono Pharmaceutical's key executives?

Ono Pharmaceutical's management team includes the following people:
  • Mr. Gyo Sagara, CEO, Pres & Representative Director
  • Mr. Shozo Matsuoka, Corp. Exec. Officer and Exec. Director of Corp. Regulatory Compliance, Safety & QA
  • Yukio Tani, Corp. Exec. Officer & Head of Corp. Communications
  • Mr. Hiroshi Ichikawa, Corp. Sr. Exec. Officer and Exec. Director of Sales & Marketing
  • Mr. Isao Ono, Exec. Officer, Director of Corp. Research & Director
  • Mr. Hiroshi Awata, VP, Exec. Officer, Tokyo Branch Head & Director
  • Mr. Toichi Takino, Exec. Officer, Exec. Director of Discovery & Research and Director
  • Mr. Toshihiro Tsujinaka, Exec. Officer, Exec. Director of Corp. Strategy & Planning and Director
  • Kiyoaki Idemitsu, Corp. Exec. Officer & Exec. Director of Clinical Devel.
  • Shinji Takai M.D., Corp. Officer, Head of Medical Affairs & Head of Data Strategy

Who are some of Ono Pharmaceutical's key competitors?

What is Ono Pharmaceutical's stock symbol?

Ono Pharmaceutical trades on the OTCMKTS under the ticker symbol "OPHLY."

How do I buy shares of Ono Pharmaceutical?

Shares of OPHLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ono Pharmaceutical's stock price today?

One share of OPHLY stock can currently be purchased for approximately $8.94.

How many employees does Ono Pharmaceutical have?

Ono Pharmaceutical employs 3,560 workers across the globe.

What is Ono Pharmaceutical's official website?

The official website for Ono Pharmaceutical is www.ono.co.jp.

How can I contact Ono Pharmaceutical?

The company can be reached via phone at (166) 263-5670.


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.